These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 21907751)
1. Development of DIVA (differentiation of infected from vaccinated animals) vaccines utilizing heterologous NA and NS1 protein strategies for the control of triple reassortant H3N2 influenza in turkeys. Wang L; Qin Z; Pantin-Jackwood M; Faulkner O; Suarez DL; Garcia M; Lupiani B; Reddy SM; Saif YM; Lee CW Vaccine; 2011 Oct; 29(45):7966-74. PubMed ID: 21907751 [TBL] [Abstract][Full Text] [Related]
2. Pathobiology of triple reassortant H3N2 influenza viruses in breeder turkeys and its potential implication for vaccine studies in turkeys. Pillai SP; Pantin-Jackwood M; Jadhao SJ; Suarez DL; Wang L; Yassine HM; Saif YM; Lee CW Vaccine; 2009 Feb; 27(6):819-24. PubMed ID: 19071183 [TBL] [Abstract][Full Text] [Related]
3. Vaccine-induced protection from egg production losses in commercial turkey breeder hens following experimental challenge with a triple-reassortant H3N2 avian influenza virus. Kapczynski DR; Gonder E; Liljebjelke K; Lippert R; Petkov D; Tilley B Avian Dis; 2009 Mar; 53(1):7-15. PubMed ID: 19431997 [TBL] [Abstract][Full Text] [Related]
4. Genetic and antigenic relatedness of H3 subtype influenza A viruses isolated from avian and mammalian species. Yassine HM; Lee CW; Suarez DL; Saif YM Vaccine; 2008 Feb; 26(7):966-77. PubMed ID: 18206275 [TBL] [Abstract][Full Text] [Related]
5. New DIVA vaccine for the protection of poultry against H5 highly pathogenic avian influenza viruses irrespective of the N-subtype. Peeters B; de Boer SM; Tjeerdsma G; Moormann R; Koch G Vaccine; 2012 Nov; 30(49):7078-83. PubMed ID: 23036502 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens. Jadhao SJ; Lee CW; Sylte M; Suarez DL Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695 [TBL] [Abstract][Full Text] [Related]
8. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza. Lee CW; Senne DA; Suarez DL Vaccine; 2004 Aug; 22(23-24):3175-81. PubMed ID: 15297071 [TBL] [Abstract][Full Text] [Related]
9. Pandemic H1N1 influenza virus in Chilean commercial turkeys with genetic and serologic comparisons to U.S. H1N1 avian influenza vaccine isolates. Kapczynski DR; Gonder E; Tilley B; Hernandez A; Hodgson J; Wojcinski H; Jiang H; Suarez DL Avian Dis; 2011 Dec; 55(4):633-41. PubMed ID: 22312984 [TBL] [Abstract][Full Text] [Related]
10. Molecular and antigenic characterization of reassortant H3N2 viruses from turkeys with a unique constellation of pandemic H1N1 internal genes. Berhane Y; Kehler H; Handel K; Hisanaga T; Xu W; Ojkic D; Pasick J PLoS One; 2012; 7(3):e32858. PubMed ID: 22470427 [TBL] [Abstract][Full Text] [Related]
11. PB1-F2 Protein Does Not Impact the Virulence of Triple-Reassortant H3N2 Swine Influenza Virus in Pigs but Alters Pathogenicity and Transmission in Turkeys. Deventhiran J; Kumar SR; Raghunath S; Leroith T; Elankumaran S J Virol; 2016 Jan; 90(1):222-31. PubMed ID: 26468540 [TBL] [Abstract][Full Text] [Related]
12. A heterologous neuraminidase subtype strategy for the differentiation of infected and vaccinated animals (DIVA) for avian influenza virus using an alternative neuraminidase inhibition test. Avellaneda G; Sylte MJ; Lee CW; Suarez DL Avian Dis; 2010 Mar; 54(1 Suppl):272-7. PubMed ID: 20521644 [TBL] [Abstract][Full Text] [Related]
13. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses. Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208 [TBL] [Abstract][Full Text] [Related]
14. Generation and evaluation of an H9N1 influenza vaccine derived by reverse genetics that allows utilization of a DIVA strategy for control of H9N2 avian influenza. Wu R; Chen Q; Zheng L; Chen J; Sui Z; Guan Y; Chen Z Arch Virol; 2009; 154(8):1203-10. PubMed ID: 19543688 [TBL] [Abstract][Full Text] [Related]
15. Progressive truncation of the Non-Structural 1 gene of H7N1 avian influenza viruses following extensive circulation in poultry. Dundon WG; Milani A; Cattoli G; Capua I Virus Res; 2006 Aug; 119(2):171-6. PubMed ID: 16464514 [TBL] [Abstract][Full Text] [Related]
16. Interspecies and intraspecies transmission of triple reassortant H3N2 influenza A viruses. Yassine HM; Al-Natour MQ; Lee CW; Saif YM Virol J; 2007 Nov; 4():129. PubMed ID: 18045494 [TBL] [Abstract][Full Text] [Related]
17. Avian influenza vaccination in North America: strategies and difficulties. Suarez DL; Lee CW; Swayne DE Dev Biol (Basel); 2006; 124():117-24. PubMed ID: 16447502 [TBL] [Abstract][Full Text] [Related]
18. Increased resistance of vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity avian influenza virus. Capua I; Terregino C; Cattoli G; Toffan A Avian Pathol; 2004 Apr; 33(2):158-63. PubMed ID: 15276982 [TBL] [Abstract][Full Text] [Related]
19. Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach. Sun Z; Wang Q; Li G; Li J; Chen S; Qin T; Ma H; Peng D; Liu X Microbiol Spectr; 2021 Oct; 9(2):e0068721. PubMed ID: 34585985 [TBL] [Abstract][Full Text] [Related]
20. [Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase]. Du J; Liu M; Liu C; Yang T; Li H Wei Sheng Wu Xue Bao; 2009 Jun; 49(6):813-9. PubMed ID: 19673419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]